Results 321 to 330 of about 95,754 (365)
Iqirvo for primary biliary cholangitis - efficacy, safety, and future directions. [PDF]
Ann Med Surg (Lond)Saleem R +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Medicina Clínica (English Edition), 2018
Primary cholangitis (cirrhosis) is a chronic cholestatic disease with an unquestionable female predominance. It is characterised by inflammation of the small and medium size bile ducts, and can eventually progress to cirrhosis. Most patients remain asymptomatic and are diagnosed by the casual finding of an anicteric biochemical cholestasis with ...
Seth N. Sclair, Cynthia Levy
semanticscholar +8 more sources
Primary cholangitis (cirrhosis) is a chronic cholestatic disease with an unquestionable female predominance. It is characterised by inflammation of the small and medium size bile ducts, and can eventually progress to cirrhosis. Most patients remain asymptomatic and are diagnosed by the casual finding of an anicteric biochemical cholestasis with ...
Seth N. Sclair, Cynthia Levy
semanticscholar +8 more sources
Primary biliary cholangitis: treatment
Current Opinion in Gastroenterology, 2021Purpose of review To discuss the most recent data regarding treatment of patients with primary biliary cholangitis (PBC) with inadequate response to ursodeoxycholic acid (UDCA). Recent findings Patients with PBC at high-risk of progressive disease are younger, have advanced fibrosis
Cazzagon N., Floreani A.
openaire +2 more sources
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
New England Journal of Medicine, 2023BACKGROUND Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis.
Kris V. Kowdley +30 more
semanticscholar +1 more source
American Journal of Gastroenterology, 2023
INTRODUCTION: Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease, and patients with inadequate response to ursodeoxycholic acid (UDCA) treatment show reduced long-term survival.
Yansheng Liu +11 more
semanticscholar +1 more source
INTRODUCTION: Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease, and patients with inadequate response to ursodeoxycholic acid (UDCA) treatment show reduced long-term survival.
Yansheng Liu +11 more
semanticscholar +1 more source
Liver international (Print), 2023
Observational studies have indicated that the incidence of primary biliary cholangitis (PBC) is higher in inflammatory bowel disease (IBD) patients than that in healthy people. However, whether the correlation is causal remains unclear.
Hongchen Zhang +3 more
semanticscholar +1 more source
Observational studies have indicated that the incidence of primary biliary cholangitis (PBC) is higher in inflammatory bowel disease (IBD) patients than that in healthy people. However, whether the correlation is causal remains unclear.
Hongchen Zhang +3 more
semanticscholar +1 more source
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
American Journal of Gastroenterology, 2019Cholestatic liver diseases encompass a broad spectrum of pathologies, with the core injury occurring at the level of cholangiocytes and progressing to hepatic fibrosis and liver dysfunction. Primary biliary cholangitis and primary sclerosing cholangitis are the most significant progressive cholangiopathies in adults. Although rare, they commonly evolve
Raquel T, Yokoda, Elizabeth J, Carey
openaire +2 more sources
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
New England Journal of MedicineBACKGROUND Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits.
G. Hirschfield +22 more
semanticscholar +1 more source